This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision (EYE) Gains From Store Opening Amid Macro Woes
by Zacks Equity Research
In terms of store expansion, National Vision (EYE) continues to see a sizable new opportunity with growth for the coming years.
Thermo Fisher (TMO) Adds New Platform to CTS Product Portfolio
by Zacks Equity Research
Thermo Fisher (TMO) launches the next-generation Gibco CTS Detachable Dynabeads platform.
Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
by Zacks Equity Research
Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Why Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Align Technologies (ALGN) Set to Acquire Cubicure GmbH
by Zacks Equity Research
Align Technologies (ALGN) announces acquisition of direct 3D printing pioneer Cubicure GmbH, backed by years of successful collaboration.
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.
3 Reasons Growth Investors Will Love Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.
Abbott (ABT) to Advance Diabetes Care With New Acquisition
by Zacks Equity Research
Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.
Charles River (CRL) Gains From Global Demand Amid FX Woes
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.
Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe
by Zacks Equity Research
Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.
LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM
by Zacks Equity Research
LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).
Globus Medical (GMED) Completes NuVasive Merger Agreement
by Zacks Equity Research
Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.
ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod
by Zacks Equity Research
The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.
Boston Scientific's (BSX) FARAPULSE System Study Data Positive
by Zacks Equity Research
Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.
Are Medical Stocks Lagging Haemonetics (HAE) This Year?
by Zacks Equity Research
Here is how Haemonetics (HAE) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.
Walgreens (WBA) OTC NARCAN Nasal Spray to be Available Soon
by Zacks Equity Research
Walgreens (WBA) is instructing Americans to administer this life-saving drug that, if given in time, can reverse the effects of an opioid overdose.
Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Inspira (IINN) Advances Foothold in Europe With Extended Deal
by Zacks Equity Research
The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.